Although preclinical investigations have established a strong correlation between cathepsin K and the occurrence of bone metastases, clinical trials have predominantly prioritized the use of cathepsin K inhibitors for treating osteoporosis and arthritis. This evidence concerns the gene CTSK and osteoporosis.